Press Releases

First monoclonal antibody licensed to help control the clinical signs associated with atopic dermatitis in dogs Targets and neutralizes interleukin-31 (IL-31), a key itch-inducing cytokine (protein) in canine atopic dermatitis Provides convenience and long-lasting relief from itch with one injection every four to eight weeks Joins Zoetis’ APOQUEL ® (oclacitinib tablet), giving the company two targeted treatment options to offer veterinarians for canine patients with atopic dermatitis Zoetis Inc . (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted the company a license for CYTOPOINT™, the first monoclonal antibody (mAb) therapy approved to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs. CYTOPOINT targets and neutralizes interleukin-31 (IL-31), a key protein involved in triggering itch in dogs. It provides fast, effective relief of itching – the hallmark sign of the allergic skin condition atopic ...

Purchases a pioneer in developing and manufacturing microfluidic “lab on a chip” diagnostics for veterinary point-of-care services for $80 million Adds to diagnostics portfolio with specialty test instruments and cartridges Gains pipeline of next-generation diagnostics to help veterinarians better detect, prevent and treat disease Continues to deploy capital to strengthen its pipeline to support future growth Zoetis Inc . (NYSE:ZTS) today announced that it has completed the purchase of Scandinavian Micro Biodevices , a pioneer in developing and manufacturing microfluidic “lab on a chip” diagnostic analyzers and tests for veterinary point-of- care services for $80 million. The acquisition adds to Zoetis’ complementary point-of-care diagnostics portfolio, giving the company an expanded and promising pipeline in this fast-growing segment of the animal health industry. Privately-held-Scandinavian Micro Biodevices (SMB) commercialized the first point-of-care, “lab on a chip” (LOC), ...

Six abstracts to be presented by Zoetis scientists Contributes to new understanding of interleukin-31 (IL-31) in canine atopic dermatitis and use of lokivetmab to inhibit the IL-31 pathway and help reduce clinical signs of atopic dermatitis Zoetis scientists will present six abstracts at the 8th World Congress of Veterinary Dermatology (WCVD) that contribute to the body of evidence supporting the use of lokivetmab, an antibody designed specifically for dogs that inhibits the canine cytokine interleukin-31 (cIL-31). The data also advance scientific understanding of the role of IL-31 in canine atopic dermatitis. The WCVD takes place May 31 to June 4 in Bordeaux, France. Data Supporting the Efficacy of Lokivetmab in Canine Atopic Dermatitis Zoetis will present the results of a randomized, double-blind, placebo-controlled dose determination trial to evaluate efficacy of three doses of lokivetmab (0.125, 0.5 or 2.0 mg/kg) in providing relief from the clinical signs of pruritus (itching) ...

First and only FDA-approved treatment calms without sedating Dogs that experience fear and anxiety in response to loud noise such as fireworks, thunder, and construction work now have a new treatment option with the launch of SILEO® (dexmedetomidine oromucosal gel), the first and only medication approved by the U.S. Food and Drug Administration (FDA) for treatment of noise aversion in dogs. Noise aversion refers to the behavioral and clinical signs of fear and anxiety experienced by dogs in response to noise. SILEO, which is being marketed in the U.S. by Zoetis Inc. (NYSE:ZTS), is available from veterinarians by prescription and can be safely administered at home by pet owners to help calm dogs without sedating for the duration of noise events. “We know that noise aversion has been difficult to treat, is stressful for pet owners and can be traumatic for their dogs. SILEO works the way veterinarians and pet owners need it to work, calming dogs while allowing them to interact normally ...

University of Surrey and Zoetis collaborate to launch vHive, New Innovation Centre GUILDFORD, SURREY, UK - April 27, 2016 - Zoetis and the University of Surrey today launched the Veterinary Health Innovation Engine (vHive), a novel multi-disciplinary centre designed to promote the development and adoption of digital innovation in animal health. Digital technologies including wearables, apps, sensors and satellites promise to transform real-time information capture for animal owners and their veterinary advisors.  This will enable improved understanding of animal health and early identification of problems in a similar manner to eHealth for people. Furthermore, creation of digital platforms in animal health and the development of sophisticated machine-learning analytics will facilitate early warning surveillance of population threats such as the Schmallenberg virus and Bluetongue epidemics we have witnessed in recent years. Speaking at the launch, Professor Alex Cook, Head of vHive at ...

Easy-to-administer chewable tablet delivers fast and persistent protection over 35 days from fleas and ticks, without losing efficacy at the end of the month Innovation from Zoetis targets growing demand for oral flea and tick medication Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Simparica TM (sarolaner) Chewables to kill adult fleas and prevent flea infestations, as well as treat and control tick infestations due to the Lone Star tick, the Gulf Coast tick, the American dog tick, and the brown dog tick. Simparica is approved for use in dogs 6 months of age or older and weighing 2.8 pounds or more. In a single-dose, tasty chewable tablet, once-monthly Simparica offers fast and persistent protection from fleas and ticks, with peak performance that lasts for a full 35 days, without losing efficacy at the end of the month.¹ “Simparica is exciting for two reasons: it acts fast to kill fleas and ticks, and it maintains its efficacy ...